{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:14:12Z","timestamp":1773033252056,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.annder.2017.06.010","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T19:01:51Z","timestamp":1500318111000},"page":"508-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rosac\u00e9e\u00a0: nouveaut\u00e9s pour une meilleure prise en charge"],"prefix":"10.1016","volume":"144","author":[{"given":"B.","family":"Cribier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2017.06.010_bib0400","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S0151-9638(11)70087-4","article-title":"Epidemiology of rosacea: updated data","volume":"138","author":"Chosidow","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2009.04.024","article-title":"Papulopustular rosacea: prevalence and relationship to photodamage","volume":"63","author":"McAleer","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0410","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1365-2133.2011.10436.x","article-title":"Prevalence of skin lesions and need for treatment in a cohort of 90,880\u00a0workers","volume":"165","author":"Augustin","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0415","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2133.2012.11037.x","article-title":"A study on the epidemiology of rosacea in the UK","volume":"167","author":"Spoendlin","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0420","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1203475416629118","article-title":"Development and evaluation of a Rosacea screening instrument (Rosascreen)","volume":"20","author":"Tan","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.annder.2017.06.010_bib0425","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jdv.13556","article-title":"Prevalence of rosacea in the general population of Germany and Russia \u2013 The RISE study","volume":"30","author":"Tan","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0430","series-title":"La rosac\u00e9e","author":"Cribier","year":"2002"},{"key":"10.1016\/j.annder.2017.06.010_bib0435","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0151-9638(11)70089-8","article-title":"Clinical presentations and classification of rosacea","volume":"138","author":"Jansen","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0440","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12385","article-title":"An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes","volume":"169","author":"Tan","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0445","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: Report of the National rosacea society expert committee on the classification and staging of Rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0450","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/jdv.13801","article-title":"Efficacy and safety of permethrin 5\u00a0% topical gel vs. placebo for rosacea: a double-blind randomized controlled clinical trial","volume":"30","author":"Raoufinejad","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0455","first-page":"4","article-title":"Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy","volume":"14","author":"Reinholz","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2017.06.010_bib0460","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","article-title":"Standard grading system for rosacea: report of the National rosacea society expert committee on the classification and staging of rosacea","volume":"50","author":"Wilkin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0465","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","article-title":"The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities","volume":"163","author":"Aksoy","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0470","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13555-016-0133-6","article-title":"Superior efficacy with ivermectin 1\u00a0% cream compared to metronidazole 0.75\u00a0% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded Attract study","volume":"6","author":"Schaller","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.annder.2017.06.010_bib0475","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaad.2007.01.048","article-title":"A pilot quality-of-life instrument for acne rosacea","volume":"57","author":"Nicholson","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0480","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjd.15122","article-title":"Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus [ROSCO] panel","volume":"176","author":"Tan","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0485","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/ijd.13491","article-title":"Epidemiology of rosacea in Colombia","volume":"56","author":"Rueda","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0490","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1473-2165.2009.00456.x","article-title":"Rosacea and rhinophyma: not curse of the Celts but Indo Eurasians","volume":"8","author":"Wollina","year":"2009","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0495","doi-asserted-by":"crossref","DOI":"10.5070\/D32010024262","article-title":"Rosacea in skin of color: not a rare diagnosis","volume":"20","author":"Al-Dabagh","year":"2014","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2017.06.010_bib0500","first-page":"1219","article-title":"Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with rosacea: an analysis by Fitzpatrick skin type","volume":"11","author":"Alexis","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0505","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamadermatol.2014.4728","article-title":"Clinical, histologic, and molecular analysis of differences between erythematotelangiectatic rosacea and telangiectatic photoaging","volume":"151","author":"Helfrich","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0510","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjd.15173","article-title":"Rosacea treatment update: recommendations from the global ROSacea COnsensus [ROSCO] panel","volume":"176","author":"Schaller","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0515","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/bjd.13956","article-title":"Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments","volume":"173","author":"van Zuuren","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0520","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5\u00a0% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0525","first-page":"56","article-title":"Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5\u00a0% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study","volume":"13","author":"Moore","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0530","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/jdv.13305","article-title":"Brimonidine gel 0.33\u00a0% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study","volume":"29","author":"Layton","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0535","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase\u00a0III clinical trials evaluating anti-inflammatory dose doxycycline (40\u2013mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0540","first-page":"316","article-title":"Efficacy and safety of ivermectin 1\u00a0% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0545","first-page":"1380","article-title":"Long-term safety of ivermectin 1\u00a0% cream vs azelaic acid 15\u00a0% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials","volume":"13","author":"Stein Gold","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0550","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1\u00a0% cream over metronidazole 0.75\u00a0% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0555","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jid.2016.01.025","article-title":"A Randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea","volume":"136","author":"Sbidian","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0560","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jid.2016.03.003","article-title":"Low-dose isotretinoin: an option for difficult-to-treat papulopustular rosacea","volume":"136","author":"van Zuuren","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0565","first-page":"505","article-title":"Systemic isotretinoin in the treatment of rosacea \u2013 doxycycline- and placebo-controlled, randomized clinical study","volume":"8","author":"Gollnick","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2017.06.010_bib0570","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ajd.12505","article-title":"Phymatous rosacea presenting with leonine facies and clinical response to isotretinoin","volume":"58","author":"Wee","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0575","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2012.04.017","article-title":"Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective \u03b2-adrenergic blocker","volume":"67","author":"Hsu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0580","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s12325-016-0380-z","article-title":"Topical ivermectin 10\u00a0mg\/g and oral doxycycline 40\u00a0mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments","volume":"33","author":"Steinhoff","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.annder.2017.06.010_bib0585","first-page":"641","article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1\u00a0% in the treatment of rosacea","volume":"6","author":"Fowler","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0590","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3109\/02713683.2015.1122810","article-title":"A randomized controlled trial of omega 3\u00a0fatty acids in rosacea patients with dry eye symptoms","volume":"41","author":"Bhargava","year":"2016","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.annder.2017.06.010_bib0595","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaad.2016.08.055","article-title":"Prevalence and risk of migraine in patients with rosacea: a population-based cohort study","volume":"76","author":"Egeberg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0600","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2013.03.027","article-title":"Migraine, triptans, and the risk of developing rosacea: a population-based study within the United Kingdom","volume":"69","author":"Spoendlin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0605","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","article-title":"Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea","volume":"13","author":"Yamasaki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.annder.2017.06.010_bib0610","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.annder.2017.06.010_bib0615","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/jid.2010.351","article-title":"TLR2\u00a0expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes","volume":"131","author":"Yamasaki","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0620","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jid.2016.10.046","article-title":"TRPV4\u00a0mediates mast cell activation in cathelicidin-induced rosacea inflammation","volume":"137","author":"Mascarenhas","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0625","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/jid.2015.141","article-title":"Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1\/Th17\u00a0pathways","volume":"135","author":"Buhl","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0630","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/jid.2012.14","article-title":"Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin","volume":"132","author":"Kanada","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0635","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaad.2016.01.023","article-title":"Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial","volume":"74","author":"Di Nardo","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0640","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2013.05.019","article-title":"Cathelicidin, kallikrein\u00a05, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15\u00a0% gel","volume":"69","author":"Coda","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0645","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13555-017-0176-3","article-title":"Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37\u00a0and KLK5, in reconstructed and ex vivo skin models","volume":"7","author":"Thibaut de M\u00e9nonville","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.annder.2017.06.010_bib0650","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/jid.2013.472","article-title":"Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor","volume":"134","author":"Two","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0655","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/jdv.13517","article-title":"Study of Demodex mites: challenges and solutions","volume":"30","author":"Lacey","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0660","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/jdv.12178","article-title":"Interest of confocal laser scanning microscopy for the diagnosis and treatment monitoring of demodicosis","volume":"28","author":"Harmelin","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0665","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1111\/jdv.14084","article-title":"Monitoring structural changes in Demodex mites under topical Ivermectin in rosacea by means of reflectance confocal microscopy: a case series","volume":"31","author":"Ruini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0670","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1365-2133.2012.11114.x","article-title":"Positive correlation between serum immunoreactivity to Demodex-associated Bacillus proteins and erythematotelangiectatic rosacea","volume":"167","author":"O\u2019Reilly","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0675","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10753-015-0264-4","article-title":"Activation of neutrophils via IP3\u00a0pathway following exposure to demodex-associated bacterial proteins","volume":"39","author":"McMahon","year":"2016","journal-title":"Inflammation"},{"key":"10.1016\/j.annder.2017.06.010_bib0680","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.micpath.2014.04.002","article-title":"Microbiota of Demodex mites from rosacea patients and controls","volume":"71\u201372","author":"Murillo","year":"2014","journal-title":"Microb Pathog"},{"key":"10.1016\/j.annder.2017.06.010_bib0685","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.12121","article-title":"Rosacea under the microscope: characteristic histological findings","volume":"27","author":"Cribier","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.annder.2017.06.010_bib0690","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.annder.2012.10.592","article-title":"(A histological and immunohistological study of vascular and inflammatory changes in rosacea)","volume":"140","author":"Perrigouard","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0695","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.12180","article-title":"Improvement in telangiectatic rosacea as a side-effect of monthly docetaxel therapy","volume":"39","author":"Tokunaga","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0700","first-page":"454","article-title":"Therapeutic response of rosacea to dobesilate","volume":"10","author":"Cuevas","year":"2005","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.annder.2017.06.010_bib0705","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/exd.12745","article-title":"Recombinant erythroid differentiation regulator 1\u00a0inhibits both inflammation and angiogenesis in a mouse model of rosacea","volume":"24","author":"Kim","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0710","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1346-8138.12687","article-title":"Propranolol, doxycycline and combination therapy for the treatment of rosacea","volume":"42","author":"Park","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0715","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/ced.12630","article-title":"Neurogenic rosacea: an uncommon and poorly recognized entity?","volume":"40","author":"Parkins","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0720","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/archdermatol.2010.413","article-title":"Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment","volume":"147","author":"Scharschmidt","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0725","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","article-title":"Neurovascular and neuroimmune aspects in the pathophysiology of rosacea","volume":"15","author":"Schwab","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.annder.2017.06.010_bib0730","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/archderm.140.11.1345","article-title":"Laser treatment of rosacea: a pathoetiological study","volume":"140","author":"Lonne- Rahm","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0735","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1152\/jn.00458.2015","article-title":"Augmented supraorbital skin sympathetic nerve activity responses to symptom trigger events in rosacea patients","volume":"114","author":"Metzler-Wilson","year":"2015","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.annder.2017.06.010_bib0740","first-page":"e76","article-title":"A new treatment regimen for rosacea: onabotulinum toxin\u00a0A","volume":"11","author":"Dayan","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0745","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2009.03472.x","article-title":"Risk factors associated with rosacea","volume":"24","author":"Abram","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0750","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2015.2230","article-title":"Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins","volume":"151","author":"Aldrich","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0755","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/jid.2015.53","article-title":"Assessment of the genetic basis of rosacea by genome-wide association study","volume":"135","author":"Chang","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2015.11.004","article-title":"Clustering of autoimmune diseases in patients with rosacea","volume":"74","author":"Egeberg","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0765","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","article-title":"Clinical, cellular, and molecular aspects in the pathophysiology of rosacea","volume":"15","author":"Steinhoff","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.annder.2017.06.010_bib0770","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jamadermatol.2013.1213","article-title":"Phymatous transformation of facial cutaneous vascular malformations: clues to phyma pathogenesis","volume":"149","author":"Voth","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0775","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2133.2011.10662.x","article-title":"The fatty acid profile of the skin surface lipid layer in papulopustular rosacea","volume":"166","author":"N\u00ed Raghallaigh","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0780","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jid.2016.12.025","article-title":"Sebaceous gland rich skin is characterized by TSLP expression and distinct immune surveillance which is disturbed in rosacea","volume":"137","author":"Dajnoki","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2017.06.010_bib0785","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jdv.13748","article-title":"Feelings of stigmatization in patients with rosacea","volume":"31","author":"Halioua","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2017.06.010_bib0395","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000444082","article-title":"Patients with rosacea have increased risk of depression and anxiety disorders: a Danish nationwide cohort study","volume":"232","author":"Egeberg","year":"2016","journal-title":"Dermatology"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963817302508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963817302508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:05:01Z","timestamp":1758971101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963817302508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":79,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0151963817302508"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2017.06.010","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rosac\u00e9e\u00a0: nouveaut\u00e9s pour une meilleure prise en charge","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2017.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}